1200.32-Effect of BIBW 2992 on lung cancer patients with EGFR mutation

• Research type

  Research Study

• Full title

  1200.32 - LUX-Lung 3; A randomised, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR (Epidermal Growth Factor Receptor) activating mutation.

• IRAS ID

  25848

• Contact name

  Sanjaykumar Popat

• Eudract number

  2008-005615-18

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  This is a randomised and open label study to investigate the efficacy and safety of a new drug, BIBW 2992 compared to chemotherapy (Pemetrexed/Cisplatin) in lung cancer patients whose tumours have mutations (spontaneous changes) in a particular gene called EGFR (epidermal growth factor receptor).

• REC name

  London - Hampstead Research Ethics Committee

• REC reference

  09/H0720/119

• Date of REC Opinion

  18 Nov 2009

• REC opinion

  Further Information Favourable Opinion